The second shortcoming is that only one primary outcome, i.e., OS, is analyzed in the enrollment; CSS and RFS are also needed to clarify the clinical role of LDHA/LDHB in ccRCC. The gene discussed is LDHA; the disease is nonpapillary renal cell carcinoma.